Valence Life Sciences, LLC
Micro VC, based in New York, New York, reporting $25.3M of fund assets across 4 funds.
Composed from this organization's classification, location and filed figures.
1 additional team member, 4 additional investments, funds and LPs, 13 events, 1 verified contact (1 firm phone)
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Nothing material in the last 180 days.
People to know
View all people- Managing DirectorWhy: Managing directorNo route on file yet
Relationship network
12 connected entities2 observed rounds1 repeat counterpartyrounds 2015 to 2018
From financing rounds and every investor named in them, Form ADV and Form D filings, the firm's funds and team, and disclosed LP commitments in the venture capital graph. A round's amount is the size of the round, not money that moved between two investors.
Some relationships on this record are counted rather than named here. They open with the full profile.
Click any name or line for the rounds and sources behind it. Line weight is rounds together; dashed lines are inferred.
- Sponsor
- Company
- Fund or vehicle
- Person
›How strength and recency are read
Co-investors are read from the rounds: three or more shared rounds is a strong observed relationship, two a repeat co-investor, one a single round. Funds and people are structural. Nothing is scored that a reader cannot check.
Darker lines were active in the last 24 months or are current; lighter lines are older or undated.
How am I connected?
Name your firm, a company or a person, and DFX finds the published routes to Valence Life Sciences, LLC: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.
See how you connect to Valence Life Sciences, LLC
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Investing
2 companies on record, 0 new in 12 months
Investments on record
What these amounts mean“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.Acquired, Public, Exited and Active are what the firm’s own portfolio card says, read on the date shown when you hover the chip; they are not deal dates. A company with no chip is one whose card states no outcome: DFX does not assume it is active.| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| CalciMedica | portfolio listing | unknown | unknown | unknown | unknown | Sep 21, 2026 | Fact Company website |
| Velicept Therapeutics, Inc. | Form D equity offering | unknown · board | Scott David Morenstein (strongly supported) | $15.5M form d sold | unknown | Jul 18, 2018 | Inference Form D |
Stated thesis versus observed behaviour
- Sectors
- biotech
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Team
1 current, 4 departed
Decision makers
- Eric Wayne Roberts · Managing DirectorWhy this person: Managing director; Named with investment responsibility
Ranked by the role the firm or its filing states, a route on file and deals led. Every reason is read from the record, never inferred. Routes are published by the person or the firm (their bio, the team page or a filing) and are revealed on a plan; data bought from a provider is never shown, and a route printed at a firm the person has since left is held back.
Investment team
How the team is orderedPartners who lead rounds first (rounds led, then deals attributed, then seniority), then the rest of the investment team, then investor relations, finance and operations. A person named by two sources under two spellings is shown once.- Managing Director
4 departed (kept with end dates)
- ANN Rachel Leheny · Managing Director · Dec 1, 2011 to Mar 24, 2014 Inference
- James E Cecil · Managing Director · Jan 1, 2011 to Mar 24, 2014 Inference
- Scott David Morenstein · Managing Director · Jan 1, 2012 to Mar 24, 2014 Inference
Contacts
1 firm phone on record, each with its source. Values open with the complete profile.
Funds and LPs
4 vehicles, 0 LPs disclosed
Funds and vehicles
What these amounts meanGAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Valence Helix Investments III | Fund | 2019 adv first reported | Mature | $2.0M Feb 25, 2020 | 12 | unknown | unknown |
| Valence Helix Investments II | Fund | 2019 adv first reported | Mature | $1.9M Feb 25, 2020 | 12 | unknown | unknown |
| Valence Helix Investments I | Fund | 2019 adv first reported | Mature | $1.6M Feb 25, 2020 | 10 | unknown | unknown |
Limited partners
Known LPs and allocators
What these amounts and dates areEach commitment is counted once across the pension tape and the allocator graph. A commitment date prints only when the source printed one; otherwise the row carries the report date. A foundation’s 990-PF line is a holding at fair value, never a commitment. Rows without a fund on the venture graph are commitments to this manager.Relationships across DFX
2 co-investors
Co-investors
- 2026-09-211 shared deal · one time
- 2026-09-211 shared deal · one time
Evidence and history
18 dated events, 35 observations from 2 sources
Timeline
- Mar 15, 2019Valence Helix Investments III first reported on Form ADV by Valence Life Sciences, LLC (Venture Capital Fund), GAV $2,045,000
- Mar 15, 2019Valence Helix Investments II first reported on Form ADV by Valence Life Sciences, LLC (Venture Capital Fund), GAV $1,850,000
- Mar 15, 2019Valence Helix Investments I first reported on Form ADV by Valence Life Sciences, LLC (Venture Capital Fund), GAV $1,650,000
- Mar 8, 2017Valence Cdk Spv, L.P. no longer reported on Form ADV by Valence Life Sciences, LLC
- Mar 24, 2014Scott David Morenstein (Managing Director) no longer on Schedule A of Valence Life Sciences, LLC
Identity and regulatory footprint
Address, phone, Form ADV filing and ownersForm ADV filed Feb 25, 2020 · 4 private fundsShowHide
Website description: Valence Life Sciences
- Headquarters
- New York, NYadviserinfo.sec.gov
- Office address
- unknownadviserinfo.sec.gov
- Business phone
- unknownadviserinfo.sec.gov
- Website
- VALENCEFUND.COM
- SEC adviser type
- Exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- Venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Feb 25, 2020
- Private funds reported
- 4 (4 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets, adviser total
- $25.3Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Classification history
Classification history
Every classification this record has carried2 on recordShowHide
- Sep 15, 2026Micro VC (confirmed, 95%)Venture manager, reported GAV $25.3M across 4 vehicles
- Sep 12, 2026Micro VC (confirmed, 95%)Venture manager, reported GAV $5.5M across 3 vehicles
Evidence
Every observation behind this profile, with its source, date and class
| Fact | Value | Effective | Class | Source |
|---|---|---|---|---|
| SEC exemption claimed | Venture capital fund adviser | Feb 25, 2020 | Fact | Form ADV |
| SEC adviser type | Exempt reporting adviser | Feb 25, 2020 | Fact | Form ADV |
| First Form ADV filing | 2012-03-13 | Feb 25, 2020 | Fact | Form ADV |
| Adv history loaded | adv-hist-1 | Sep 12, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2020-02-25 | Feb 25, 2020 | Fact | Form ADV |
| Venture share of reported funds | 1 | Feb 25, 2020 | Fact | Form ADV |
| Business phone | Feb 25, 2020 | Fact | Form ADV | |
| Contact page url | Sep 16, 2026 | Fact | ||
| Description | Sep 16, 2026 | Fact | ||
| Description | Sep 14, 2026 | Fact | ||
| Headquarters | New York, NY | Feb 25, 2020 | Fact | Form ADV |
| Office address | Feb 25, 2020 | Fact | Form ADV | |
| Legal form | Limited Liability Company | Feb 25, 2020 | Fact | Form ADV |
| Portfolio page | Sep 16, 2026 | Fact | ||
| Portfolio page | Sep 14, 2026 | Fact | ||
| Private funds reported | 4 | Feb 25, 2020 | Fact | Form ADV |
| Private fund gross assets (reported) | $25.3M | Feb 25, 2020 | Fact | Form ADV |
| Stated sectors | biotech “sector words on the home page” | Sep 16, 2026 | Fact | |
| Stated sectors | biotech “sector words on the home page” | Sep 14, 2026 | Fact | |
| Team page | Sep 16, 2026 | Fact | ||
| Team page | Sep 14, 2026 | Fact | ||
| Venture funds reported | 4 | Feb 25, 2020 | Fact | Form ADV |
| Website | Feb 25, 2020 | Fact | Form ADV | |
| Site title | Sep 16, 2026 | Fact | ||
| Site title | Sep 14, 2026 | Fact |
How this is scored
Scores, classification basis and filing advisersMicro VC, confirmedShowHide
Venture manager, reported GAV $25.3M across 4 vehicles
- importance
- gav: 0.12 · funds: 0.58 · people: 0.04 · investments: 0.18 · co investors: 0.12
- active deployment
- investments 12m: 0 · fund raising 18m: 0 · people joined 12m: 0 · vintage within 3y: 0 · latest investment at: not scored
- emerging manager
- fund count: 7 · reported gav: $25.3M · first adv filing: 2012-03-13 · years since first filing: 14.6
Fits, record history and connections
scored matches for this investor, every identity change, every edge
Record history
- Adviser's first ADV filing2012-03-13source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.